These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 1149212)

  • 1. Studies of the absorption and removal of propranolol in hypertensive patients during therapy.
    Chidsey CA; Morselli P; Bianchetti G; Morganti A; Leonetti G; Zanchetti A
    Circulation; 1975 Aug; 52(2):313-8. PubMed ID: 1149212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propranolol.
    Shand DG
    Dis Mon; 1974 Oct; ():1-31. PubMed ID: 4606956
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of food on the intravenous and oral dose kinetics of propranolol in the dog.
    Bai SA; Walle UK; Walle T
    J Pharmacokinet Biopharm; 1985 Jun; 13(3):229-41. PubMed ID: 4087163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No stereoselective first-pass hepatic extraction of propranolol.
    Jackman GP; McLean AJ; Jennings GL; Bobik A
    Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variable first-pass elimination of propranolol following single and multiple oral doses in hypertensive patients.
    Wargin WA; Sawchuk RJ; McBride JW; McCoy HG; Rylander ML
    Eur J Drug Metab Pharmacokinet; 1982; 7(3):183-9. PubMed ID: 7173272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of propranolol during pregnancy.
    O'Hare MF; Kinney CD; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1984; 27(5):583-7. PubMed ID: 6519163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.
    Evans GH; Shand DG
    Clin Pharmacol Ther; 1973; 14(4):487-93. PubMed ID: 4723255
    [No Abstract]   [Full Text] [Related]  

  • 8. Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man.
    Evans GH; Shand DG
    Clin Pharmacol Ther; 1973; 14(4):494-500. PubMed ID: 4723256
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical pharmacokinetics of propranolol.
    Routledge PA; Shand DG
    Clin Pharmacokinet; 1979; 4(2):73-90. PubMed ID: 378502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics and cardiac effects of propranolol in humans.
    Ochs HR; Grube E; Greenblatt DJ; Knüchel M; Bodem G
    Klin Wochenschr; 1982 May; 60(10):521-5. PubMed ID: 7098380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of propranolol: a review.
    Shand DG
    Postgrad Med J; 1976; 52 Suppl 4():22-25. PubMed ID: 787953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of ageing on the hepatic clearance of propranolol.
    Castleden CM; George CF
    Br J Clin Pharmacol; 1979 Jan; 7(1):49-54. PubMed ID: 760742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of drug concentration measurements in studies of the therapeutic response to propranolol.
    Chidsey C; Pine M; Favrot L; Smith S; Leonetti G; Morselli P; Zanchetti A
    Postgrad Med J; 1976; 52 Suppl 4():26-32. PubMed ID: 967771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing.
    Wells PG; Feely J; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1983 May; 33(5):603-8. PubMed ID: 6839632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between oral propranolol and hydralazine.
    McLean AJ; Skews H; Bobik A; Dudley FJ
    Clin Pharmacol Ther; 1980 Jun; 27(6):726-32. PubMed ID: 7379440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of propranolol in the dog.
    Tse FL; Sanders TM; Reo JP
    Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.
    Evans GH; Nies AS; Shand DG
    J Pharmacol Exp Ther; 1973 Jul; 186(1):114-22. PubMed ID: 4198771
    [No Abstract]   [Full Text] [Related]  

  • 18. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.
    Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
    Clin Pharmacol Ther; 1980 Jan; 27(1):22-31. PubMed ID: 7351114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers.
    Bowman SL; Hudson SA; Simpson G; Munro JF; Clements JA
    Br J Clin Pharmacol; 1986 May; 21(5):529-32. PubMed ID: 3718810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of age on the hepatic clearance of propranolol in rats.
    Iwamoto K; Watanabe J; Araki K; Deguchi N; Sugiyama H
    J Pharm Pharmacol; 1985 Jul; 37(7):466-70. PubMed ID: 2863348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.